Owen Mumford Ltd
http://www.owenmumford.com/us/about/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Owen Mumford Ltd
Finance Watch: More Good To Come? CG Oncology Grosses $380m In Year’s First IPO
Public Company Edition: CG Oncology grossed $380m in the first biopharma IPO in the US in 2024. Follow-on offerings have been robust recently, with Edgewise and Immatics grossing $240m and $175m, respectively.
Finance Watch: Lexeo Launches 20th US Biopharma IPO In 2023
Public Company Edition: Lexeo raised $100m to advance its genetic medicines. Also, Blue Owl Capital acquired funds managed by Cowen Healthcare Investments, gaining about $1bn in life science assets, BMS priced $4.5bn in notes to fund its Mirati purchase and Viridian raised $185m in a private placement.
FTC’s Test Case Opposing Amgen-Horizon Deal Ends With No-Bundling Agreement
Commission pursued merger challenge to halt pharma practices it believes can stifle competition and keep drug prices high. Other large biopharma transactions may face similar challenges as FTC pursues its new merger program.
FTC's Merger Concerns Remain Despite Amgen’s ‘Bare Commitment’ Not To Bundle Horizon Drugs
The commission seeks a preliminary injunction by 31 October to block the closing of the proposed Amgen-Horizon merger. Harvard Professor Aaron Kesselheim, FTC’s expert, says Amgen could circumvent a commitment not to bundle its and Horizon's products. The Pfizer-Seagen merger agreement also gets a second request for information.
Company Information
- Industry
- Medical Devices
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice